Eritoran is a synthetic glycolipid anti-inflammatory/immunomodulatory drug - a lipid A analogue that binds MD-2 and blocks activation of the Toll-like receptor 4 (TLR4) pathway, proposed for COVID-19 to reduce excessive host inflammatory signaling.
Recent:Saito.
Sep 15 |
et al., CMI Communications, doi:10.1016/j.cmicom.2026.105223 | Eritoran and Apremilast in hospitalized patients with COVID-19: the REMAP-CAP Immune Modulation-2 Domain |
| 26% higher mortality (p=0.69), 7% lower progression (p=1), and 1% improvement (p=0.99). RCT 104 hospitalized patients with COVID-19 showing no significant difference in organ support-free days or mortality with eritoran (TLR4 antagonist) vs. placebo. | ||